Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) Gross Margin (2016 - 2025)

Fortress Biotech has reported Gross Margin over the past 11 years, most recently at 69.93% for Q4 2025.

  • Quarterly results put Gross Margin at 69.93% for Q4 2025, up 713.0% from a year ago — trailing twelve months through Dec 2025 was 67.94% (up 581.0% YoY), and the annual figure for FY2025 was 66.92%, up 479.0%.
  • Gross Margin for Q4 2025 was 69.93% at Fortress Biotech, up from 67.36% in the prior quarter.
  • Over the last five years, Gross Margin for FBIO hit a ceiling of 94.4% in Q4 2023 and a floor of 4144.26% in Q2 2023.
  • Median Gross Margin over the past 5 years was 58.93% (2022), compared with a mean of 491.54%.
  • Biggest five-year swings in Gross Margin: plummeted -348873bps in 2023 and later surged 420582bps in 2024.
  • Fortress Biotech's Gross Margin stood at 45.62% in 2021, then crashed by -4528bps to 2020.33% in 2022, then skyrocketed by 105bps to 94.4% in 2023, then plummeted by -33bps to 62.8% in 2024, then rose by 11bps to 69.93% in 2025.
  • The last three reported values for Gross Margin were 69.93% (Q4 2025), 67.36% (Q3 2025), and 69.91% (Q2 2025) per Business Quant data.